ACC2-Selective Pharmaceutical Composition for NAFLD Without Lipid Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) lack an ACC2-selective inhibitor that effectively addresses the disease without causing side effects such as increased plasma triglycerides or decreased platelet counts.
Innovation Solution
A pharmaceutical composition comprising a compound with high ACC2-selective inhibitory action, represented by Formula (I), which does not cause side effects like increased plasma triglycerides or decreased platelets, thereby improving metabolic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If an ACC1/2 dual inhibitor is used to treat NAFLD, then fatty acid synthesis is inhibited and liver fat is reduced, but plasma triglycerides increase and platelet concentration decreases
Solution Approach 1:
The invention segments the inhibition target from both ACC1 and ACC2 to only ACC2. The compound of Formula (I) is designed to selectively inhibit ACC2 while sparing ACC1, thereby achieving liver fat reduction without the adverse effects caused by ACC1 inhibition such as decreased platelet concentration and increased plasma triglycerides.
Solution Approach 2:
The invention applies local quality by creating a compound with selective inhibitory action on ACC2 specifically. The molecular structure of Formula (I) is optimized to interact preferentially with ACC2's active site, providing localized inhibition at the target enzyme level while leaving other isoforms unaffected.
2Object-generated harmful factors
If a selective ACC2 inhibitor is developed to avoid side effects, then platelet concentration and plasma triglycerides are maintained, but the ability to effectively treat NASH and fibrosis must be ensured
Solution Approach 1:
The invention employs feedback mechanisms through preclinical and clinical studies to validate that ACC2-selective inhibition achieves the desired therapeutic effect. Animal studies demonstrated reduction in liver fat and fibrosis markers, and early clinical data confirmed safety and efficacy, providing feedback that the selective inhibition strategy is reliable for treating NASH.
Solution Approach 2:
The invention changes the key parameter of enzyme selectivity from dual inhibition to selective ACC2 inhibition. By modifying the molecular parameters of the inhibitor compound (Formula (I)), the invention achieves a shift in selectivity profile that maintains therapeutic efficacy while improving the safety parameter by avoiding ACC1-related side effects.
3Ease of operation
If current therapies are used for NASH, then some symptomatic relief may be achieved, but no approved therapy exists to reduce fibrosis and steatosis effectively
Solution Approach 1:
The invention introduces a new intermediary compound (Formula (I)) that acts as a selective ACC2 inhibitor. This compound serves as a mediator between the therapeutic goal of reducing liver fat and fibrosis and the biological pathway of fatty acid synthesis, providing an effective treatment mechanism that is currently unavailable with approved therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively treats and prevents NAFLD, including conditions like NASH, liver fibrosis, and hepatocellular carcinoma, while avoiding adverse effects on triglycerides and platelet counts, and can be combined with other drugs for enhanced efficacy.
Implementation Method 1
ACC is an enzyme that carboxylates acetyl-CoA to convert it into malonyl-CoA, and is involved in metabolism of fatty acids. The compound of Formula (I) has high ACC2-selective inhibitory action
Data Source
AI summary
Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I):whereinR1 is haloalkyl or non-aromatic carbocyclyl,R2 is a hydrogen atom or halogen,R3 is halogen,ring A is a group represented by the formula:-L1- is —O—(CH2)—, —(CH2)2—, or the like,R4 is alkyl or haloalkyl, andR5 is alkylcarbonyl or carbamoyl,or a pharmaceutically acceptable salt thereof.